These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4045924)

  • 1. Hydroxy derivatives of tamoxifen.
    Foster AB; Jarman M; Leung OT; McCague R; Leclercq G; Devleeschouwer N
    J Med Chem; 1985 Oct; 28(10):1491-7. PubMed ID: 4045924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, conformational considerations, and estrogen receptor binding of diastereoisomers and enantiomers of 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,2-diphenylbutane (dihydrotamoxifen).
    McCague R; Leclercq G
    J Med Chem; 1987 Oct; 30(10):1761-7. PubMed ID: 3656352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
    McCague R; Leclercq G; Jordan VC
    J Med Chem; 1988 Jul; 31(7):1285-90. PubMed ID: 3385723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
    Murphy CS; Langan-Fahey SM; McCague R; Jordan VC
    Mol Pharmacol; 1990 Nov; 38(5):737-43. PubMed ID: 2233701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
    Kraft KS; Ruenitz PC; Bartlett MG
    J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts.
    Jarman M; Leung OT; Leclercq G; Devleeschouwer N; Stoessel S; Coombes RC; Skilton RA
    Anticancer Drug Des; 1986 Nov; 1(3):259-68. PubMed ID: 3450298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.
    Robertson DW; Katzenellenbogen JA; Hayes JR; Katzenellenbogen BS
    J Med Chem; 1982 Feb; 25(2):167-71. PubMed ID: 7057423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
    Roos W; Oeze L; Löser R; Eppenberger U
    J Natl Cancer Inst; 1983 Jul; 71(1):55-9. PubMed ID: 6575210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.
    McCague R; Leclercq G; Legros N; Goodman J; Blackburn GM; Jarman M; Foster AB
    J Med Chem; 1989 Dec; 32(12):2527-33. PubMed ID: 2585441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour.
    Top S; Kaloun el B; Vessières A; Leclercq G; Laïos I; Ourevitch M; Deuschel C; McGlinchey MJ; Jaouen G
    Chembiochem; 2003 Aug; 4(8):754-61. PubMed ID: 12898627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.
    Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M
    J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
    Ruenitz PC; Bagley JR; Mokler CM
    J Med Chem; 1982 Sep; 25(9):1056-60. PubMed ID: 7131484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrosourea and nitrosocarbamate derivatives of the antiestrogen tamoxifen as potential estrogen receptor-mediated cytotoxic agents in human breast cancer cells.
    Wei LL; Katzenellenbogen BS; Robertson DW; Simpson DM; Katzenellenbogen JA
    Breast Cancer Res Treat; 1986; 7(2):77-90. PubMed ID: 3719114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies.
    McCague R; Kuroda R; Leclercq G; Stoessel S
    J Med Chem; 1986 Oct; 29(10):2053-9. PubMed ID: 3761324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxy or counterpart function with the estrogen receptor.
    Borgna JL; Scali J
    Eur J Biochem; 1991 Aug; 199(3):575-85. PubMed ID: 1868844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro.
    Jordan VC; Koch R; Langan S; McCague R
    Endocrinology; 1988 Apr; 122(4):1449-54. PubMed ID: 3345720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.